A060590 Stock Overview
Provides various pharmaceutical products in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A060590 from our risk checks.
CTCBIO Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩7,700.00 |
| 52 Week High | ₩15,900.00 |
| 52 Week Low | ₩7,690.00 |
| Beta | 0.44 |
| 11 Month Change | -4.35% |
| 3 Month Change | -11.29% |
| 1 Year Change | -22.85% |
| 33 Year Change | -11.09% |
| 5 Year Change | 13.91% |
| Change since IPO | 51.02% |
Recent News & Updates
Shareholder Returns
| A060590 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -3.5% | -2.9% | -1.0% |
| 1Y | -22.8% | 6.2% | 7.4% |
Return vs Industry: A060590 underperformed the KR Pharmaceuticals industry which returned 6.2% over the past year.
Return vs Market: A060590 underperformed the KR Market which returned 7.4% over the past year.
Price Volatility
| A060590 volatility | |
|---|---|
| A060590 Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.1% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A060590 has not had significant price volatility in the past 3 months.
Volatility Over Time: A060590's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 233 | Mingoo Lee | www.ctcbio.com |
CTCBIO Inc. provides various pharmaceutical products in South Korea and internationally. The company offers animal and human pharmaceuticals; feed additives and ingredients; and functional food products. It also provides cardiovascular, gastrointestinal, osteoporosis, antibiotic, smoking cessation, antifungal and antiviral, antiepileptic, allergic rhinitis, dermatology and genito-urinory, allergic rhinitis and antihistamine, neuropsychiarty, intestinal disorders, X-ray, diabetes, anti-inflammatory and arthritis, and harmones, as well as CTC covid-19 IgM/IgG combo test, a quick antibody test kit on covid-19.
CTCBIO Inc. Fundamentals Summary
| A060590 fundamental statistics | |
|---|---|
| Market cap | ₩184.10b |
| Earnings (TTM) | -₩14.16b |
| Revenue (TTM) | ₩135.82b |
1.4x
P/S Ratio-13.0x
P/E RatioIs A060590 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A060590 income statement (TTM) | |
|---|---|
| Revenue | ₩135.82b |
| Cost of Revenue | ₩91.06b |
| Gross Profit | ₩44.76b |
| Other Expenses | ₩58.92b |
| Earnings | -₩14.16b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -592.28 |
| Gross Margin | 32.96% |
| Net Profit Margin | -10.43% |
| Debt/Equity Ratio | 38.8% |
How did A060590 perform over the long term?
See historical performance and comparison